Zeynel Mungan

Last updated
Zeynel Mungan
Born (1952-12-21) December 21, 1952 (age 71)
Diyarbakir, Turkey
NationalityTurkish
Alma mater Istanbul University
Known for Mungan Syndrome
Scientific career
Fields Medicine, Gastroenterology
Institutions Istanbul University
Tulane University
The American Hospital of Istanbul

Zeynel Mungan (born December 21, 1952) is a Turkish citizen and Professor of Medicine, recognized for his academic achievements in the field of gastroenterology.

Contents

Career

Zeynel Mungan, born in Diyarbakir, Turkey in 1952, received his medical degree at the Medical Faculty of Istanbul University in 1977. He was appointed to Associate Professor in 1988 and Professorship in 1995 in the same university. Between the years 1990 and 1992, Dr. Mungan worked as a Research Associate Professor at New Orleans, Tulane University and has been awarded the Kemal Akdamar GI Research Fellowship.

He was Head of Gastroenterohepatology in Istanbul University between 2005 and 2010 and President of the Istanbul Branch of Turkish Gastroenterology Association between 1999 and 2007. [1]

Dr. Mungan is a Fellow of the American College of Gastroenterology, Fellow of the European Board of Gastroenterology and a member of the Turkish Gastroenterology Association. He is the author of more than 100 papers published in international and Turkish journals and gastroenterology textbooks, mostly in the fields of endoscopy, GI peptides, pituitary adenylate cyclase-activating peptide (PACAP), irritable bowel syndrome (IBS), acid-peptic diseases and gastrointestinal motility. Dr. Mungan is also on the editorial board of Gastroenterology Research and Practice, [2] Best Research and Practice Clinical Gastroenterology, [3] and The Turkish Journal of Gastroenterology. [4]

Family

He is married with two children and lives in Istanbul.

Membership in professional organizations

Works

Articles

  1. Mungan Z, Ertan A, Hammer RA, Arimura A: Effect of pituitary adenylate cyclase activating polypeptide on rat pancreatic exocrine secretion. Peptides, 12:559-562, (1991).
  2. Mungan Z, Ozmen V, Ertan A, Arimura A: Pituitary adenylate cyclase activating polypeptide-27 (PACAP-27) inhibits pentagastrin-stimulated gastric acid secretion in conscious rats. Regulatory Peptides, 38:199-206, (1992).
  3. Mungan Z, Ozmen V, Ertan A, Coy DH, Baylor LM, Rice JC, Rossowski WJ: Structural requirements for galanin inhibition of pentagastrin-stimulated gastric acid secretion in conscious rats: Effect of potent novel rat galanin agonist. Eur J Pharmacol, 214:53-57, (1992).
  4. Rossowski WJ, Zacharia S, Mungan Z, Ozmen V, Ertan A, Baylor LM, Jiang NY, Coy DH:Reduced gastric acid inhibitory effect of a pGIP(1-30) NH2 fragment with potent pancreatic amylase inhibitory activity. Regulatory Peptides, 39:9-17, (1992).
  5. Mungan Z, Arimura A, Ertan A, Rossowski WJ, Coy DH: Pituitary adenylate cyclase activating polypeptide relaxes rat gastrointestinal smooth muscle. Scan J Gastroenterol, 27:375-380, (1992).
  6. Coy DH, Mungan Z, Rossowski WJ, Cheng BL, Lin JT, Mrozinski JE, Jensen RT: Development of a potent bombesin receptor antagonist with prolonged in vivo inhibitory activity on bombesin-stimulated amylase and protein release in the rat. Peptides, 13:775-781, (1992).
  7. Sotaniemi EA, Mungan Z, Risteli L, Stenback FG, Ökten A, Yalcın S, Risteli J: Serum type III procollagen and basal membrane antigens in hepatitis B virus liver disease. Eur J Intern Med, 3:131-139, (1992).
  8. Rossowski WJ, Zacharia S, Jiang NY, Mungan Z, Mills MR, Ertan A, Coy DH: Galanin; Structure-dependent effect on pancreatic amylase secretion and jejunal strip contraction. Eur J Pharmacol, 240:259-267, (1993).
  9. Mungan Z, Hammer RA, Akarca US, Komaki G, Ertan A, Arimura A: Effect of PACAP on gastric acid secretion in rats. Peptides, 16:1051-1056, (1995).
  10. Gürel S, Beşışık F, Demir K, Mungan Z, Kaymakoğlu S, Boztaş G, Çakaloğlu Y, Yeğinsü O, Ökten A: After eradication of Helicobacter pylori infection relapse is a serious problem in Turkey. J Clin Gastroenterol, 28:241-244, (1999)
  11. Demir K, Okten A, Kaymakoglu S, Dinçer D, Beşışık F, Çevikbaş U, Özdil S, Boztaş G, Mungan Z, Çakaloğlu Y: Tuberculous peritonitis- reports of 26 cases, detailing diagnostic and therapeutic problems. Eur J Gastroenterology & Hepatology, 13:581-585, (2001)
  12. Besısık F, Sürücü F, Mungan Z, Dinçer D, Kapran Y, Kaymakoglu S, Çevikbaş U. Helicobacter pylori eradication lowers esophageal sphincter pressures in functional dyspepsia patients. Hepato-Gastroenterology, 48:1772-5 (2001)
  13. Dinçer D, Besısık F, Sahin E, Demir K, Tuncer I, Cevikbas U, Mungan Z, Boztas G, Ozdil S, Cakaloglu Y, Otken A: Intestinal metaplasia of the gastric cardia: a study from Turkey. Hepato-Gastroenterology, 49:1153-6 (2002)
  14. Danalioglu A, Kaymakoglu S, Mungan Z, Karaca C, Demir K, Durakoglu Z, Besisik F, Boztas G, Cakaloglu Y, Okten A. Efficacy of cyclosporin in severe ulcerative colitis attack. Turk J Gastroenterol. 13:130-3 (2002)
  15. Durakoglu Z, Boztas G, Sezgil A, Kaymakoglu S, Dincer D, Ozdil S, Besisik F, Mungan Z, Okten A. Alverine induced toxic hepatitis: a case report. Turk J Gastroenterol. 13:226-8, (2002)
  16. Kaymakoglu S, Kahraman T, Kudat H, Demir K, Cakaloglu Y, Adalet I, Dincer D, Besısık F, Boztas G, Sozen AB, Mungan Z, Okten A. Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients. Dig Dis Sci, 48:556-60 (2003)
  17. Mungan Z, Akyuz F, Bugra Z, Yonal O, Ozturk S, Acar A, Cevikbas U. A family of visceral myopathy; with pseudo-obstruction, megaduodenum, Barrett's esophagus and cardiac abnormalities. Am J Gastroenterol, 98:2556-60 (2003)
  18. Ozdil S, Demir K, Boztas G, Danalioglu A, Karaca C, Akyuz F, Aksoy N, Kaymakoglu S, Mungan Z, Besisik F, Cakaloglu Y, Okten A. Crohn's disease; analysis of 105 patients. Hepatogastroenterology. 50 Suppl 2:cclxxxvii-ccxci.(2003)
  19. Danalioglu A, Kaymakoglu S, Mungan Z, Karaca C, Demir K, Durakoglu Z, Besisik F, Boztas G, Cakaloglu Y, Okyen A. Cyclosporin for severe ulcerative colitis attacks. Hepatogastroenterology. 50 Suppl 2:ccxcviii-ccc.(2003)
  20. Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A. Terlipressin and albumin combination treatment in hepatorenal syndrome. Hepatogastroenterology. 50 Suppl 2:ccciii-cccv. (2003)
  21. Cetin K, Gungor B, Isik A, Ahmet D, Filiz A, Nevzat A, Sadakat O, Cengiz D, Zeynel M. The effect of pneumatic balloon dilatation on gastric emptying in patients with achalasia. Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccci-cccii.
  22. Ozdil S, Akyüz F, Pinarbaşı B, Demir K, Karaca Ç, Kaymakoğlu S, Mungan Z, Beşışık F, Cakaloğlu Y, Okten A. Ulcerative colitis: analyses of 116 cases (do extraintestinal manifestations effect the time to catch remission?). Hepatogastroenterology, 51:768-70 (2004)
  23. Karaca Ç, Pınarbaşı B, Danalıoğlu A, Akyüz F, Kaymakoğlu S, Özdil S, Boztaş G, Mungan Z. Liver abscess as a rare complication of Crohn's disease: A case report. Turk J Gastroenterol, 15:45-48, (2004)
  24. Akbayir N, Alkim C, Erdem L, Sökmen HM, Sungun A, Baş T, Turgut S, Mungan Z. Heterotopic gastric mucosa in the cervical esophagus (inlet patch): Endoscopic prevalence, histological and clinical characteristics. Journal of Gastroenterology and Hepatology, 19:891-6 (2004)
  25. Boztaş G, Mungan Z, Özdil S, Akyüz F, Karaca C, Demir K, Kaymakoglu S, Besısık F, Çakaaloglu Y, Ökten A. Pneumatic balloon dilatation in primary achalasia: The long term following results . Hepatogastroenterology. 52:475-80,(2005)
  26. Poturoğlu Ş, Mungan Z, Boztaş G, Kaymakoğlu S, Ozdil S, Akyüz F, Aksoy N, Kamaci S, Pınarbaşı B, Çevikbaş U, Ökten A. Peritoneal amyloidosis caused by familial mediterranean fever. J Gastroenterol Hepatol, 20:325-6, (2005)
  27. Akbayir N, Sokmen HM, Calis AB, Bolukbas C, Erdem L, Alkim C, Sakiz D, Mungan Z. Heterotopic gastric mucosa in the cervical esophagus: could this play a role in the pathogenesis of laryngopharyngeal reflux in a subgroup of patients with posterior laryngitis? Scand J Gastroenterol. 40:1149-56 (2005)
  28. Ibrisim D, Cakaloglu Y, Akyuz F, Karadag A, Ozdil S, Besisik F, Mungan Z, Okten A. Treatment of hepatic hydrothorax with terlipressin in a cirrhotic patient. Scand J Gastroenterol. 41:862-5, (2006)
  29. Akyuz F, Ibrisim D, Balik E, Yonal O, Kaymakoglu S, Bugra D, Mungan Z. Evaluation of malignancy risk and endoscopic follow up in achalasia: Case report. Turk J Gastroenterol. 17:46-49, (2006)
  30. Yonal O, Hatırnaz O, Akyuz F, Ozbek U, Demir K, Kaymakoglu S, Otken A, Mungan Z. HFE gene mutation, chronic liver disease, and iron overload In Turkey. Dig Dis Sci. 52:3298-302 (2007).
  31. Akyuz F, Demir K, Ozdil S, Aksoy N, Poturoglu S, Ibrisim D, Kaymakoglu S, Besisik F, Boztas G, Cakaloglu Y, Mungan Z, Cevikbas U. Otken A. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig Dis Sci. 52:2359-67, (2007)
  32. Yonal O, Hatirnaz O, Akyuz F, Koroglu G, Ozbek U, Cefle K, Mungan Z. Definition of C282Y mutation in a hereditary hemochromatosis family from Turkey. Turk J Gastroenterol. 18:53-57 (2007)
  33. Deglincerti A, De Giorgio R, Cefle K, Devoto M, Pippucci T, Castegnaro G, Panza E, Barbara G, Cogliandro RF, Mungan Z, Palanduz S, Corinaldesi R, Romeo G, Seri M, Stanghellini V. A novel locus for syndromic chronic idiopathic intestinal pseudo-obstruction maps to chromosome 8q23-q24. Eur J Hum Genet. 15:889-97 (2007)
  34. Demir K, Akyuz F, Ozdil S, Aksoy N, Kaymakoglu S, Poturoglu S, Akyüz U, Besisik F, Boztas G, Mungan Z, Cevikbas U, Cakaloglu Y, Okten A. What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis? Ann Hepatol. 6:92-6 (2007)
  35. Mungan Z, Pinarbaşi B, Kaymakoğlu S. Eosinophilic esophagitis: Case report. Turk J Gastroenterol. 18:100-2 (2007)
  36. Ahishali E, Pinarbasi B, Akyuz F, Ibrisim D, Kaymakoglu S, Mungan Z. A case of Aeromonas hyDROPhyhila enteritis in the course of ulcerative colitis. Eur J Intern Med. 18:430-1 (2007)
  37. Ahishali E, Boztas A, Akyuz F, Ibrisim D, Poturoglu S, Pinarbasi B, Ozdil S, Mungan Z. Response to Hepatitis B Vaccination in Patients with Celiac Disease. Dig Dis Sci. (2007)
  38. Ermis F, Akyuz F, Demir K, Besisik F, Boztas G, Mungan Z. Rapidly progressive HCV cirrhosis in a hypogammaglobulinemic patient. Intern Med. 47:415-7 (2008)
  39. Pınarbaşı B, Poturoglu Ş, Yanar H, Güven K, Akyüz F, Dizdaroğlu F, Güllüoğlu M, Taviloğlu K, Kaymakoğlu S, Mungan Z. A rare cause of hemosuccus pancreaticus: Primary splenic artery aneurysm ruptured into pancreatic serous cystadenoma. Turk J Gastroenterol 19:57-63 (2008)
  40. Mungan Z, Pınarbaşı B, Akyuz F, Bektas H, Akyuz A. Wireless endoscopy capsule remaining safely for a long time. Dig Dis Sci 53:1422-3 (2008)
  41. Ibrişim D, Cevikbaş U, Akyüz F, Poturoğlu S, Ahishali E, Güllüoğlu M, Demir K, Beşişik F, Boztaş G, Ozdil S, Cakaloğlu Y, Mungan Z, Okten A, Kaymakoğlu S. Intestinal metaplasia in portal hypertensive gastropathy: a frequent pathology. Eur J Gastroenterol Hepatol. 20:874-80 (2008)
  42. Akyuz F, Mungan Z. Diagnostic capability of capsule endoscopy in small bowel diseases. Gastroenterology Research 2:81-5 (2009)
  43. Pinarbasi B, Kaymakoglu S, Matur Z, Akyuz F, Demir K, Besisik F, Ozdil S, Boztas G, Cakaloglu Y, Mungan Z, Okten A. Are acquired hepatocerebral degeneration and hepatic myelopathy reversible? J Clin Gastroenterol43:176-81 (2009)
  44. Mungan Z, Pinarbasi B, Bakir B, Gulluoglu M, Baran B, Akyuz F, Demir K, Kaymakoglu S. Congenital portal vein aneurysm associated with peliosis hepatis and intestinal lymphangiectasia. Gastroenterol Res Pract. 2009:479264 (2009)
  45. Poturoglu S, Kaymakoglu S, Gurel Polat N, Ibrisim D, Ahishali E, Akyuz F, Badur S, Demir K, Mungan Z. A new agent for tumour necrosis factor-alpha inhibition: In vitro effects of dipyridamole in Crohn's disease. Scand J Clin Lab Invest. 69:696-702 (2009)
  46. Akyüz F, Arici S, Ermiş F, Mungan Z. Utility of esophageal manometry and pH-metry in gastroesophageal reflux disease before surgery. Turk J Gastroenterol. 20:261-5 (2009)
  47. Ahishali E, Demir K, Ahishali B, Akyuz F, Pinarbasi B, Poturoglu S, Ibrisim D, Gulluoglu M, Ozdil S, Besisik F, Kaymakoglu S, Boztas G, Cakaloglu Y, Mungan Z, Canberk Y, Okten A. Electron microscopic findings in non-alcoholic fatty liver disease: is there a difference between hepatosteatosis and steatohepatitis? J Gastroenterol Hepatol. 25:619-26 (2010)
  48. Yonal O, Akyuz F, Demir K, Ciftci S, Keskin F, Pinarbasi B, Uyanikoglu A, Issever H, Ozdil S, Boztas G, Besisik F, Kaymakoglu S, Cakaloglu Y, Mungan Z, Okten A. Decreased Prohepcidin Levels in Patients with HBV-Related Liver Disease: Relation with Ferritin Levels. Dig Dis Sci. 55:3548-51(2010)
  49. Akyuz F, Pinarbasi B, Ermis F, Uyanikoglu A, Demir K, Ozdil S, Besisik F, Kaymakoglu S, Boztas G, Mungan Z. Is portal hypertensive enteropathy an important additional cause of blood loss in portal hypertensive patients? Scand J Gastroenterol. 45:1497-502 (2010)
  50. Lanas A, Aabakken L, Fonseca J, Mungan Z, Papatheodoridis GV, Piessevaux H, Cipolletta L, Nuevo J, Tafalla M. Clinical predictors of poor outcomes among patients with nonvariceal upper gastrointestinal bleeding in Europa. Aliment Pharnacol Ther. 33:1225-33 (2011)
  51. Sen F, Pinarbaşi B, Işsever H, Akyüz F, Mungan Z, Kaymakoğlu S. Postprandial platelet-poor plasma 5-hyroxytryptamine concentrations during diarrhea and constipation periods of alternating type irritable bowel syndrome patients. Turk J Gastroenterol 22:270-8 (2011)
  52. Ermis F, Akyuz F, Uyanıkoglu A, Kurt R, Pinarbasi B, Nazik H, Kaymakoglu S, Mungan Z. Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. South Med J 104:579-83 (2011)
  53. Akyüz F, Cakaloğlu Y, Pinarbaşi B, Demir K, Akyüz U, Ozdil S, Beşişik F, Boztaş G, Mungan Z, Kaymakoğlu S. Anticoagulant therapy and Budd-Chiari syndrome : is it successful ? Hepatogastroenterology 58:900-3 (2011)
  54. Ermis F, Akyuz F, Arici S, Uyanikoglu A, Pinarbasi B, Demir K, Ozdil S, Besisik F, Kaymakoglu S, Boztas G, Cuhadaroglu C, Mungan Z. Effect of proton pump inhibitor (PPI) treatment in obstructive sleep apnea syndrome: An esophageal impedance-pHmetry study. Hepatogastroenterology 58:110-1 (2011)
  55. Uyanikoglu A, Akyuz F, Ermis F, Arici S, Bas G, Cakirca M, Baran B, Mungan Z. Does cholecystectomy increase the esophageal alkaline reflux? Evaluation by Impedance-pH technique. J Neurogastroenterol Motil. 18:187-93 (2012)
  56. Ermis F, Akyuz F, Mungan Z. Recurrence of Helicobacter pylori after eradication in patient with peptic ulcer. South Med J. 105:322-3 (2012)
  57. Uyanıkoglu A, Danalıoğlu A, Akyüz F, Ermiş F, Güllüoğlu M, Kapran Y, Demir K, Özdil S, Beşışık F, Boztaş G, Mungan Z, Kaymakoğlu S. Etiologic factors of duodenal and gastric ulcers. Turk J Gastroenterol 23:99-103 (2012)
  58. Mungan Z. Prevalence and demographic determinants of gastroesophageal reflux disease (GERD) in the Turkish general population: A population-based sectional study. Turk J Gastroenterol 23:323-32 (2012)
  59. Akyuz F, Besisik F, Ustek D, Ekmekçi C, Uyar A, Pınarbasi B, Demir K, Ozdil S, Kaymakoglu S, Boztas G, Mungan Z, Gul A. Association of the MEFV gen variations with inflammatory bowel disease in Turkey. J Clin Gastroenterol Jul 17 (2012)

Book Contributions

  1. Mungan, Z.: Üst Gastrointestinal sistem kanamaları. Acil Dahiliye, Ed. S.Çalangu-K.Güler, 4.Baskı, İstanbul 1995, s:315-334, 5.Baskı 1997, 6.Baskı 2002
  2. Mungan, Z : Tükrük salgısı bozuklukları (s:1139-41), Disfaji (s:1141-52), Dispepsi (s:1217-42), Hematemez, Melena ve hematokezi (s:1243-66), Karında gaz (s:1267-75). Semptomdan Teşhise. Ed. V.Aleksanyan, 10.Baskı, İstanbul 2000
  3. Mungan, Z.: Özofagus Hastalıkları (s:1-36), Üst Gastrointestinal Sistem Kanamaları (s: 75-88), İrritabl Barsak Sendromu (s: 243-250), Divertikülozis Koli (s: 251-254), Pnömotozis Sistoides İntestinalis (s:255-256). Gastroenterohepatoloji. Ed. A.Ökten, İstanbul 2001
  4. Mungan, Z : Gastroözofageal Reflü Hastalığında Tanı. Aktüel Gastroenteroloji ve Hepatoloji, Ed E.Göksoy, İstanbul 2001, s:3-9, 2.baskı 2003
  5. Mungan, Z: Non-kardiak göğüs ağrısı. (s: 73-75). Klinik Gastroenteroloji. Ed. F.Memik, Nobel, İstanbul 2005
  6. Mungan, Z: Asit gelişimine neden olan periton hastalıkları (s:137-154). Klinik Pratikte Asitli Hasta Ed. A. Ökten. İstanbul. 2005
  7. Mungan, Z: Gastroenteropankreatik hormon ve peptidler (s:1-16), Gastrinoma (s:69-76). GEP NET gastroenteropankreatik nöroendokrin tümörler. Ed. Y.Çakaloğlu. İstanbul. 2006
  8. Mungan, Z: Gastrointestinal sistem hastalıklarına yaklaşım (s:785-794), Özofagus hastalıkları (s:795-814). İç Hastalıkları. Ed. K.Büyüköztürk. Istanbul 2007
  9. Demir K, Mungan Z: Periton, mezenter, omentum ve diafragma hastalıkları (s:927-940). İç Hastalıkları. Ed. K.Büyüköztürk. Istanbul 2007
  10. Mungan Z: Gastroözofageal reflü hastalığı (s:60-77), Proton pompası inhibitörleri (s.104-113). Gastroenteroloji. Ed.Z.Mungan, Istanbul 2010

Related Research Articles

<span class="mw-page-title-main">Urea breath test</span> Medical test for a bacterial infection

The urea breath test is a rapid diagnostic procedure used to identify infections by Helicobacter pylori, a spiral bacterium implicated in gastritis, gastric ulcer, and peptic ulcer disease. It is based upon the ability of H. pylori to convert urea to ammonia and carbon dioxide. Urea breath tests are recommended in leading society guidelines as a preferred non-invasive choice for detecting H. pylori before and after treatment.

<i>Helicobacter pylori</i> Species of bacteria

Helicobacter pylori, previously known as Campylobacter pylori, is a gram-negative, flagellated, helical bacterium. Mutants can have a rod or curved rod shape, and these are less effective. Its helical body is thought to have evolved in order to penetrate the mucous lining of the stomach, helped by its flagella, and thereby establish infection. The bacterium was first identified as the causal agent of gastric ulcers in 1983 by the Australian doctors Barry Marshall and Robin Warren. In 2005 they were awarded the Nobel Prize in Physiology or Medicine for this discovery.

<span class="mw-page-title-main">Famotidine</span> Medication that reduces stomach acid

Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.

<span class="mw-page-title-main">Malabsorption</span> Abnormality in absorption of food nutrients across the gastrointestinal tract

Malabsorption is a state arising from abnormality in absorption of food nutrients across the gastrointestinal (GI) tract. Impairment can be of single or multiple nutrients depending on the abnormality. This may lead to malnutrition and a variety of anaemias.

<span class="mw-page-title-main">Keratin 20</span> Protein-coding gene in the species Homo sapiens

Keratin 20, often abbreviated CK20, is a protein that in humans is encoded by the KRT20 gene.

<span class="mw-page-title-main">Atrophic gastritis</span> Medical condition

Atrophic gastritis is a process of chronic inflammation of the gastric mucosa of the stomach, leading to a loss of gastric glandular cells and their eventual replacement by intestinal and fibrous tissues. As a result, the stomach's secretion of essential substances such as hydrochloric acid, pepsin, and intrinsic factor is impaired, leading to digestive problems. The most common are vitamin B12 deficiency possibly leading to pernicious anemia; and malabsorption of iron, leading to iron deficiency anaemia. It can be caused by persistent infection with Helicobacter pylori, or can be autoimmune in origin. Those with autoimmune atrophic gastritis (Type A gastritis) are statistically more likely to develop gastric carcinoma, Hashimoto's thyroiditis, and achlorhydria.

Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract and accessory organs of digestion, including the esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus. The symptoms relate to the organ affected and can include obstruction, abnormal bleeding or other associated problems. The diagnosis often requires endoscopy, followed by biopsy of suspicious tissue. The treatment depends on the location of the tumor, as well as the type of cancer cell and whether it has invaded other tissues or spread elsewhere. These factors also determine the prognosis.

The Bristol stool scale is a diagnostic medical tool designed to classify the form of human faeces into seven categories. It is used in both clinical and experimental fields.

<span class="mw-page-title-main">Stool guaiac test</span> Test for the presence for occult blood

The stool guaiac test or guaiac fecal occult blood test (gFOBT) is one of several methods that detects the presence of fecal occult blood. The test involves placing a fecal sample on guaiac paper and applying hydrogen peroxide which, in the presence of blood, yields a blue reaction product within seconds.

<span class="mw-page-title-main">Eosinophilic gastroenteritis</span> Medical condition

Eosinophilic gastroenteritis, also known as eosinophilic enteritis, is a rare and heterogeneous condition characterized by patchy or diffuse eosinophilic infiltration of gastrointestinal (GI) tissue, first described by Kaijser in 1937. Presentation may vary depending on location as well as depth and extent of bowel wall involvement and usually runs a chronic relapsing course. It can be classified into mucosal, muscular and serosal types based on the depth of involvement. Any part of the GI tract can be affected, and isolated biliary tract involvement has also been reported. The stomach is the organ most commonly affected, followed by the small intestine and the colon.

Gluten-sensitive enteropathy–associated conditions are comorbidities or complications of gluten-related gastrointestinal distress. GSE has key symptoms typically restricted to the bowel and associated tissues; however, there are a wide variety of associated conditions. These include bowel disorders, eosinophilic gastroenteritis and increase with coeliac disease (CD) severity. With some early onset and a large percentage of late onset disease, other disorders appear prior to the coeliac diagnosis or allergic-like responses markedly increased in GSE. Many of these disorders persist on a strict gluten-free diet, and are thus independent of coeliac disease after triggering. For example, autoimmune thyroiditis is a common finding with GSE.

<span class="mw-page-title-main">Portal hypertensive gastropathy</span> Changes in the mucosa of the stomach in patients with portal hypertension

Portal hypertensive gastropathy refers to changes in the mucosa of the stomach in patients with portal hypertension; by far the most common cause of this is cirrhosis of the liver. These changes in the mucosa include friability of the mucosa and the presence of ectatic blood vessels at the surface. Patients with portal hypertensive gastropathy may experience bleeding from the stomach, which may uncommonly manifest itself in vomiting blood or melena; however, portal hypertension may cause several other more common sources of upper gastrointestinal bleeding, such as esophageal varices and gastric varices. On endoscopic evaluation of the stomach, this condition shows a characteristic mosaic or "snake-skin" appearance to the mucosa of the stomach.

<span class="mw-page-title-main">Lentinan</span> Chemical compound

Lentinan is a polysaccharide isolated from the fruit body of shiitake mushroom.

Helicobacter pylori eradication protocols is a standard name for all treatment protocols for peptic ulcers and gastritis in the presence of Helicobacter pylori infection. The primary goal of the treatment is not only temporary relief of symptoms but also total elimination of H. pylori infection. Patients with active duodenal or gastric ulcers and those with a prior ulcer history should be tested for H. pylori. Appropriate therapy should be given for eradication. Patients with MALT lymphoma should also be tested and treated for H. pylori since eradication of this infection can induce remission in many patients when the tumor is limited to the stomach. Several consensus conferences, including the Maastricht Consensus Report, recommend testing and treating several other groups of patients but there is limited evidence of benefit. This includes patients diagnosed with gastric adenocarcinoma, patients found to have atrophic gastritis or intestinal metaplasia, as well as first-degree relatives of patients with gastric adenocarcinoma since the relatives themselves are at increased risk of gastric cancer partly due to the intrafamilial transmission of H. pylori. To date, it remains controversial whether to test and treat all patients with functional dyspepsia, gastroesophageal reflux disease, or other non-GI disorders as well as asymptomatic individuals.

<span class="mw-page-title-main">Itopride</span> Chemical compound

Itopride (INN; brand name Ganaton) is a prokinetic benzamide derivative. These drugs inhibit dopamine and acetylcholine esterase enzyme and have a gastrokinetic effect. Itopride is indicated for the treatment of functional dyspepsia and other gastrointestinal conditions. It is a combined D2 receptor antagonist and acetylcholinesterase inhibitor. Itopride is the dimethoxy analog of trimethobenzamide.

<span class="mw-page-title-main">Troxipide</span> Chemical compound

Troxipide is a drug used in the treatment of gastroesophageal reflux disease. Troxipide is a systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum. Troxipide is currently marketed in Japan (Aplace), China (Shuqi), South Korea (Defensa), and India (Troxip). It is used for the management of gastric ulcers, and amelioration of gastric mucosal lesions in acute gastritis and acute exacerbation of chronic gastritis.

Alverine is a drug used for functional gastrointestinal disorders. Alverine is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus.

FibroTest, known as FibroSure in the US, is a biomarker test that uses the results of six blood serum tests to generate a score that is correlated with the degree of liver damage in people with a variety of liver diseases. FibroTest has the same prognostic value as a liver biopsy. FibroSure uses quantitative results of five serum biochemical markers, α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, gamma glutamyl transpeptidase (GGT), with a patient’s age and gender to generate a measure of fibrosis and necroinflammatory activity in the liver.

<span class="mw-page-title-main">Pepsinogen 3, group I (pepsinogen A)</span> Protein-coding gene in the species Homo sapiens

Pepsinogen 3, group I is a protein that in humans is encoded by the PGA3 gene.

Shomron Ben-Horin is an Israeli physician, a co-founder & Chief Medical Officer of Evinature, and professor of medicine at the Tel-Aviv University.

References

  1. ↑ "Zeynel Mungan - Scholarly Contributions". Hindawi Publishing Corporation. Retrieved October 19, 2010.
  2. ↑ "Gastroenterology Research and Practice - Editorial Board". Hindawi. Retrieved October 28, 2010.
  3. ↑ "Best Practice & Research: Clinical Gastroenterology - Editorial Board". Elsevier. Retrieved October 28, 2010.
  4. ↑ "The Turkish Journal of Gastroenterology - Editorial Board". Turkgastro. Retrieved October 28, 2010.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.